[16]
Burke SP, Stratton K, Baciu A, Eds. The future of drug safety: promoting and protecting the health of the public. National Academies Press 2007.
[33]
Handen BL, Johnson CR, McAuliffe-Bellin SJ, Hardan AY. Safety and efficacy of Donepezil in children and adolescents with autism: Behavioral measures. Int Public Health J 2010; 2: 125-34.
[34]
Rao LG, Guns E, Rao AV. Lycopene: its role in human health and disease. Agro Food 2003; 7: 25-30.
[78]
Herbert M, Sage C. Autism and EMF? Plausibility of a pathophysiological link - Part I. Pathophysiology 2013; 20(3): 191-209.
[79]
Blizinsky KD. Macroscopic and Microscopic Gray Matter Aberrations in Schizophrenia: Temporal Dynamics, Cognitive Correlates, and Genetic Agency (Doctoral dissertation, Northwestern University)
[116]
Costa RM, Federov NB, Kogan JH, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. nature 2002; 415(6871): 526-30.
[167]
Infante JR, Janku F, Tolcher AW, et al. Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.
[172]
Burrows F, Kessler L, Chen J, et al. KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors. Experimental and Molecular Therapeutics 2017; 77(13): 5168.
[173]
Burrows FJ, Kessler L, Wu T, et al. 11q13 amplification selects for sensitivity to the ERK inhibitor KO-947 in squamous cell carcinomas. Experimental and Molecular Therapeutics 2018; 78(13): 3885.
[174]
Kessler L, Wu T, Guo X, et al. KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics. Poster ENA 2016; 69: S126.
[177]
Bhagwat SV, McMillen WT, Cai S, et al. Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations. Cancer Res 2017; 77(13 Supplement): 4973.
[178]
Pant S, Bendell JC, Sullivan RJ, et al. A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts). J Clinical Oncol 2019; 37(15_suppl): 3001.
[182]
Nunn PA, Berner B, Masjedizadeh MR. PRINCIPIA BIOPHARMA Inc, assignee. Compositions for ileo-jejunal drug delivery. United States patent application US, 2018.
[184]
Miermont AM, Pflicke H, Guan H, Chinnasamy H, Thomas C, Rudloff U. Direct inhibition of ERK1/2 by VTX-11e leads to increased induction of apoptosis in a subset of pancreatic cancer cell lines as compared to MEK1/2 inhibition by selumetinib (AZD6244). Cancer Re 2013; 73(8 Supplement): 5538.
[186]
Swamy N, Sundaresha HM. Women, Infants Hospital of RI Inc, assignee. Compositions and Methods for Cancer Treatment. United States patent application US, 2010.
[187]
Swamy N. Women, Infants Hospital of RI Inc, assignee. Compositions and methods for cancer treatment. United States patent US 8,853,188, 2014.